Groupama Asset Managment Raises Stake in AbbVie Inc. $ABBV

Groupama Asset Managment boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 7.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 160,541 shares of the company’s stock after buying an additional 10,854 shares during the quarter. Groupama Asset Managment’s holdings in AbbVie were worth $37,172,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ABBV. Norges Bank purchased a new position in AbbVie in the second quarter valued at about $4,288,200,000. Wellington Management Group LLP increased its stake in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Laurel Wealth Advisors LLC raised its holdings in shares of AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after purchasing an additional 5,675,095 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in AbbVie by 169.3% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after purchasing an additional 2,969,202 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its stake in AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ABBV. Piper Sandler raised their target price on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Royal Bank Of Canada initiated coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. Guggenheim reiterated a “buy” rating on shares of AbbVie in a research note on Thursday, March 12th. Evercore lowered their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Trading Down 5.1%

Shares of AbbVie stock opened at $208.47 on Thursday. The company’s 50-day moving average price is $223.76 and its 200-day moving average price is $224.84. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a market cap of $368.62 billion, a price-to-earnings ratio of 88.34, a PEG ratio of 0.76 and a beta of 0.34.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Alloy Therapeutics signed a multi‑year collaboration with AbbVie to advance a next‑generation antibody discovery platform, providing upfront and milestone payments and potential pipeline upside. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: Legendary investor Ken Fisher has AbbVie among notable portfolio moves for 2026, signaling continued institutional interest that can support the stock over the medium term. AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
• Positive Sentiment: Zacks highlights AbbVie as a strong value pick based on style scores and fundamentals, which may attract value-oriented buyers amid short‑term weakness. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Neutral Sentiment: Technically, ABBV slipped below its 50‑day moving average, signaling short‑term weakness to traders but it remains above the 200‑day average, so the long‑term trend is intact. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
• Neutral Sentiment: Market commentary (MSN/Benzinga) notes the share move largely reflects competitor progress rather than new AbbVie-specific fundamentals—useful for context but not new company data. What’s Going On With AbbVie Stock Today?
• Neutral Sentiment: High‑level policy reporting shows TrumpRx price lists aren’t uniformly cheaper than the UK, a reminder of ongoing pricing and regulatory scrutiny in pharma but not an AbbVie‑specific action today. TrumpRx lists many medicines at prices higher than paid in UK
• Negative Sentiment: FDA approved J&J’s oral IL‑23 inhibitor (Icotyde), the first oral peptide that blocks IL‑23 and a direct competitive threat to Skyrizi/Tremfya; J&J expects this class could reach blockbuster sales, increasing pressure on AbbVie’s pricing and market share in psoriasis. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: several outlets report ABBV shares fell sharply today after the J&J approval, indicating investor concern about near‑term revenue impact for Skyrizi. AbbVie (ABBV) Shares Plunge Nearly 5% as FDA Clears J&J’s Rival Psoriasis Treatment
• Negative Sentiment: Legal risk: a U.S. appeals court revived a whistleblower suit accusing big drugmakers of overcharging programs for low‑income patients, reviving potential litigation and settlement exposure for major pharma names. Big drugmakers must face US overcharge claims on medications for low-income patients

Insider Buying and Selling at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.